Targeted Therapy
Approved for: NSCLC
Biomarker: MET Exon 14 Skipping

Tepotinib (Tepmetko) is a FDA-approved treatment for adults with metastatic non-small cell lung cancer (NSCLC) who are harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

Related Research News